Oncology

Latest News

Patients with SCLC in the tarlatamab group had significantly longer overall survival, with a median of 13.6 months vs 8.3 months in the chemotherapy group. | Image credit: mi_viri - stock.adobe.com

Tarlatamab Improves SCLC Outcomes After Platinum Chemotherapy

By Jared Kaltwasser

June 19th 2025

Median overall survival was 5 months longer in patients with small cell lung cancer (SCLC) who received tarlatamab instead of chemotherapy after progression following platinum-based chemotherapy.

The data presented at ASCO reflect patients seen during 2 community health fairs designed to reach underserved populations in Georgia. | Image credit: NIKCOA - stock.adobe.com

Teledermatology Shows Promise to Reduce Disparities in Skin Cancer Screening

By Jared Kaltwasser

June 18th 2025

Patients in the cemiplimab group had superior disease-free survival vs placebo. | Image credit: Medical Works - stock.adobe.com

Cemiplimab Improves Disease-Free Survival in High-Risk, Advanced CSCC

By Jared Kaltwasser

June 13th 2025

The approval covers use of pembrolizumab as a single agent in the neoadjuvant setting, followed by adjuvant treatment with pembrolizumab in combination with radiotherapy with or without cisplatin after surgery, and then continued as a single agent. | Image credit: wladimir1804-stock.adobe.com

FDA Approves Perioperative Pembrolizumab in Resectable HNSCC

June 13th 2025

FDA approval-Olivier Le Moal-stock.adobe.com.jpeg

Mitomycin Intravesical Solution Gains FDA Approval for Recurrent Low-Grade NMIBC

By Giuliana Grossi

June 12th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

Dr Stacey W. McCullough Discusses High-Cost Therapies and Me-Too Drugs

December 13th 2015

Dr Stacey W. McCullough Discusses High-Cost Therapies and Me-Too Drugs

Stacey W. McCullough, PharmD, senior vice president of pharmacy at Tennessee Oncology, discussed strategies for managing high-cost treatments, the impact of me-too drugs, and how clinical pathways can help physicians make treatment decisions at the point of care.

This Week in Managed Care: December 12, 2015

December 12th 2015

This Week in Managed Care: December 12, 2015

This week in managed care, an analysis found the penalty for being uninsured will exceed the cost of insurance for most Americans in 2016, thousands met for the annual meeting of the American Society of Hematology, and Horizon Blue Cross Blue Shield's OMNIA plan gets good news and bad news in New Jersey.

December 11th 2015

Alectinib for ALK-Positive NSCLC Approved

Surabhi Dangi-Garimella, PhD

Within 3 months of being granted priority review, alectinib (Alecensa) has been approved for patients with advanced ALK-positive non-small cell lung cancer (NSCLC) whose disease has progressed or who cannot tolerate crizotinib

December 11th 2015

NCCS Responds to CMS, Demands Flexibility With Alternative Payment Models

Surabhi Dangi-Garimella, PhD

The National Coalition for Cancer Survivorship has submitted comments to CMS, providing feedback on the Merit-Based Incentive Payment System and Alternative Payment Models proposed by CMS as it transitions toward value-based reimbursement.

Dr Yousuf Zafar Explains Interventions to Combat Rising Drug Prices

December 11th 2015

Dr Yousuf Zafar Explains Interventions to Combat Rising Drug Prices

When considering how to rectify the rising prices of drugs, there are a number of interventions at multiple levels that can work to decrease costs to patients and the price of the drug, explained Yousuf Zafar, MD, MHS, associate professor in the Division of Medical Oncology at Duke Cancer Institute.

December 11th 2015

Is There a Mathematical Resolution to the Cost-Versus-Value Debate?

Bruce Feinberg, DO Lincy S. Lal, PharmD, PhD J. Michael Swint, PhD

Solutions proposed by patient advocates and physicians to control costs provide approaches to valuing new drug/treatments compared with 1 or several prevailing standards of care. Increasingly, however, the debate over cost is transitioning to a debate over value.

December 11th 2015

Managing Costs and Enhancing the Value of Oncology Care

Surya Singh, MD Christine Sawicki, RPh, MBA Ken Vander Pyl Alan Lotvin, MD

Management of high and rising costs in oncology requires a multifaceted approach using both innovative strategies and pragmatic tools. In this article, we discuss several factors that influence the costs of oncology care.

December 11th 2015

Maximizing Value of Freestanding and Outpatient Hospital Setting in Cancer Care Delivery

Constantine Mantz, MD

A unique collaboration between 21st Century Oncology and Lee Memorial Hospital showed marked improvements in efficiencies, care, and patient experience.

December 10th 2015

Health IT-Assisted Population-Based Preventive Cancer Screening: A Cost Analysis

Douglas E. Levy, PhD Vidit N. Munshi, MA Jeffrey M. Ashburner, PhD, MPH Adrian H. Zai, MD, PhD, MPH Richard W. Grant, MD, MPH Steven J. Atlas, MD, MPH

An automated cancer screening outreach tool implemented in a mature health information technology environment can achieve cost savings through reduced clinician time devoted to screening efforts.

December 10th 2015

What We're Reading: 1 Million New Sign-Ups for ACA Insurance

What we're reading, December 10, 2015: the Affordable Care Act has signed up 1 million new enrollees; Medicare patients spend more on oral cancer drugs than food each year; and the CDC found life expectancy remains at 79 years for the third year in a row.

December 10th 2015

Partial Mastectomy Findings at Yale Could Add Value for Patient and Payer

Surabhi Dangi-Garimella, PhD

Research conducted at the Yale Cancer Center has found that a procedure known as cavity shave margins could avoid unnecessary follow-up surgeries and save time and costs.

December 10th 2015

"Financial Toxicity": A New Term, but Not a New Reality for Many Cancer Patients

A cancer survivor shares her experience and frustrations with cancer care costs and looks to changes within the healthcare system to improve the value of care in the future.

December 9th 2015

Insurance Status Can Compromise Outcomes in CML

Surabhi Dangi-Garimella, PhD

Research presented during a health outcomes session at the recently concluded annual meeting of the American Society of Hematology evaluated the influence of patients’ insurance status on clinical outcomes of CML.

December 9th 2015

Cooling Cap Approved for Chemotherapy-Related Alopecia

The DigniCap Cooling System reduces the frequency and severity of alopecia during chemotherapy in breast cancer patients.

December 9th 2015

ACS/ASCO Offer Guidelines for Primary Care Clinicians Caring for Survivors of Breast Cancer

Surabhi Dangi-Garimella, PhD

The workgroup that generated the guideline included experts in primary care, gynecology, surgical oncology, medical oncology, radiation oncology, and nursing, along with a cancer survivor who provided a patient perspective.

December 8th 2015

Abundant Optimism at the ASH/FDA Joint Symposium on New Drug Approvals in Multiple Myeloma

Surabhi Dangi-Garimella, PhD

Primary clinical reviewers from the FDA and 2 clinician experts provided their unique perspectives on the safety, efficacy, and potential for clinical integration of 3 recently approved agents for multiple myeloma: daratumumab (Darzalex), ixazomib (Ninlaro), and elotuzumab (Empliciti).

Dr Robert Green Explains Challenges, Promise of Big Data in Oncology

December 8th 2015

Dr Robert Green Explains Challenges, Promise of Big Data in Oncology

The challenge with data in oncology is making sense of it and connecting it in a way that clinicians can make insights that inform the care they provide patients in real time, said Robert J. Green, MD, vice president of clinical strategy and senior medical director at Flatiron Health.

December 8th 2015

Novel Combinations in Multiple Myeloma and Lymphoma

Michael R. Page, PharmD, RPh Surabhi Dangi-Garimella, PhD

Results from a subgroup analysis of the phase 3 ENDEAVOR study and a phase 2 study in diffuse large B cell lymphoma patients were presented at the annual meeting of the American Society of Hematology.

December 8th 2015

ASH Leverages Recommendations From Other Medical Organizations, Advising Hematologists to Choose Wisely

Surabhi Dangi-Garimella, PhD

Members from the American Society of Hematology (ASH)'s Choosing Wisely Task Force presented 5 recommendations on Monday, December 7, 2015, at the 57th annual meeting of ASH, in Orlando, Florida.

December 7th 2015

Do Hematologists Believe APMs Afford Fair Value? An Open Discussion at ASH

Surabhi Dangi-Garimella, PhD

On the second day of the annual meeting of the American Society of Hematology, physicians got together to discuss the real-world needs of alternate payment models in hematology.

December 7th 2015

Study Shows Academic Hospitals More Adept at Caring for ALL Patients

Surabhi Dangi-Garimella, PhD

During a health outcomes session on the second day of the American Society of Hematology meeting, data presented from a study conducted at the University of Nebraska Medical Center suggested that the site of care bears a significant influence on the outcomes of patients with acute lymphoblastic leukemia.

December 6th 2015

Importance of Patient-Reported Outcomes and Quality-of-Life Measures in Myeloid Disease

Surabhi Dangi-Garimella, PhD

Two posters presented at the annual meeting of the American Society of Hematology discussed patient-reported outcomes measures and quality-of-life indicators as supportive tools for treatment in individuals being treated for acute myeloid leukemia and myelodysplastic syndrome.

December 6th 2015

How Do You Develop, and Successfully Incorporate, PROs in Hematology? Experts Chime in at ASH

Surabhi Dangi-Garimella, PhD

Presenters at an education session, titled Patient-Reported Outcomes in Hematology, addressed the importance of embracing the patient perspective in healthcare delivery, on the second day of the annual meeting of the American Society of Hematology, being held December 5-8, in Orlando, Florida.

December 5th 2015

Experts Share Concepts of Quality Measures and Pay-for-Performance at the Annual ASH Meeting

Surabhi Dangi-Garimella, PhD

At the annual meeting of the American Society of Hematology, providers brooded over implications of quality measures and how they will influence clinical practice in the coming years.

December 5th 2015

New Hematology Drugs: Progress and Challenges Discussed at the 57th ASH Meeting

Surabhi Dangi-Garimella, PhD

An early session on the first day of the annual meeting and exposition of the American Society of Hematology, being held December 5-8, 2015, in Orlando, Florida, saw presentations on the promise of newly approved hematology/oncology agents, in addition to the challenges that clinicians face in treating patients with these drugs.

December 4th 2015

5 Things to Look for at the Annual Meeting of the American Society of Hematology

Surabhi Dangi-Garimella, PhD

As the annual meeting of the American Society of Hematology kicks off on Saturday, December 5, 2015, a lot of new clinical data will be presented, practice-changing treatments will be introduced, and new healthcare policies will be discussed.

December 3rd 2015

What Is the True Financial Impact of Prescription Medications? Advera Health Explains

Surabhi Dangi-Garimella, PhD

In a study published in the Journal of Managed Care & Specialty Pharmacy, the authors present a rating system that includes downstream costs following treatment to estimate the real-world financial impact of the drug.

December 2nd 2015

Antidepressant Use Safe for Stress in Breast Cancer, Says Kaiser Study

Surabhi Dangi-Garimella, PhD

An exhaustive study published by Kaiser Permanente in the Journal of the National Cancer Institute has confirmed that antidepressants do not cause recurrence in breast cancer patients treated with tamoxifen.

December 2nd 2015

Stress a Significant Determinant of Breast Cancer Outcomes

Surabhi Dangi-Garimella, PhD

A study published in the journal Breast Cancer Research and Treatment cognitive-behavioral stress management introduced early in care management can improve breast cancer outcomes.

December 1st 2015

Consider Race Prior to Neoadjuvant Breast Cancer Chemotherapy, Oncologists Recommend

Surabhi Dangi-Garimella, PhD

A new study suggests that a poor response to neoadjuvant chemotherapy-frequently administered to black, Hispanic, and Asian women-could dictate survival rates in breast cancer.

...

115 116 117 118 119 120 121 122 123

...

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions